21 November 2012
British Pharmacological Society President to advise Scottish Medicines Consortium (21.11.12)
Jonathan Brüün, Chief Executive of the British Pharmacological Society (BPS), announced:
“The British Pharmacological Society is pleased to note our President Professor Philip Routledge has been asked to undertake a review of the Scottish Medicines Consortium’s processes for the assessment of new medicines. His appointment will be as an independent expert, tasked with reviewing current processes against those found elsewhere.
“Professor Routledge will be ideally placed to fulfil this role given his significant expertise in and commitment to promoting clinically effective and cost-effective use of medicines. I’m sure our members will join in congratulating him, and be reassured that the continued contribution of clinical pharmacologists to the work of Health Technology Appraisal bodies in the UK further highlights the value of pharmacology in improving patients’ health and wellbeing.”
Notes to editors
BPS is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects.
Clinical pharmacology is the medical specialty dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.
About the Scottish Medicines Consortium
The Scottish Medicines Consortium (SMC) appraises all newly licensed medicines and provides advice to NHS Boards on their clinical and cost-effectiveness. Currently, if a medicine is accepted for use by the SMC then individual health boards set the criteria for prescribing it. If the medicine is not accepted then health boards do not make it routinely available. However, clinicians can prescribe medicines that are not accepted for routine use by the SMC for individual patients in certain circumstances by special request through Individual Patient Treatment Requests.
BPS Press Office T. 020 7239 0184
M. 07811 378957